Assay Development Service Offered for Homogenous ELISA Conversions

The homogenous AlphaLISA assay analyzes a wide range of biomarkers and other analytes commonly measured in pharmaceutical and biopharmaceutical research and development and pre-clinical studies in drug discovery. An assay development service to facilitate traditional ELISA conversion to this new enabling technology is also available.

AlphaLISA assays are especially designed for custom applications requiring the detection of low abundance or proprietary biomarkers and biologic therapeutics for which no commercial assay kits are available or are incompatible with complex samples such as serum or plasma. The AlphaLISA technology also offers pharmaceutical laboratories an automated solution for screening common analytes in a high-throughput format.

The AlphaLISA assay and the flexible, customized assay development service were developed by PerkinElmer (Waltham, MA, USA).

"Classical ELISA assays have always required many cumbersome wash-steps, which not only take more time and effort on the part of the lab personnel, but the washing can also interfere in the analyte detection and introduce variability into the results,” said Richard Eglen, vice president and general manager of the discovery and research reagents business of PerkinElmer Life and Analytical Sciences. "By offering a homogenous alternative to ELISA, labs can easily automate these assays for greater productivity and throughput while achieving higher sensitivity and therefore more accurate, relevant data.”


Related Links:
PerkinElmer